Administering systemic chemotherapy improves survival for patients with resectable CRCLM

Share :
Published: 9 Jul 2024
Views: 9
Dr Giacomo Bregni - Francis Crick Institute, London, England

Dr Giacomo Bregni talks to ecancer about his EORTC RP-2145 trial.

This systematic review and meta-analysis pooled individual patient data from four randomised phase 3 trials to evaluate the impact of systemic chemotherapy on patients with resectable colorectal cancer liver metastases (CRCLM).

The results showed that administering systemic chemotherapy, whether post-operatively or peri-operatively, significantly reduces the risk of recurrence or progression and is associated with a trend towards better overall survival.

This study, the largest of its kind, supports the use of systemic chemotherapy in improving outcomes for these patients.